Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Jahan S. Khalili1, Shujuan Liu1, Tania G. Rodríguez-Cruz1, Mayra Whittington1, Seth Wardell1, Chengwen Liu1, Minying Zhang1, Zachary A. Cooper4, Dennie T. Frederick4, Yufeng Li1, Min Zhang2, Richard W. Joseph1, Chantale Bernatchez1, Suhendan Ekmekcioglu1, Elizabeth Grimm1, Laszlo G. Radvanyi1, Richard E. Davis2, Michael A. Davies1,3, Jennifer A. Wargo4, Patrick Hwu1, and Gregory Lizée1

Abstract

Purpose: In this study, we assessed the specific role of BRAF(V600E) signaling in modulating the expression of immune regulatory genes in melanoma, in addition to analyzing downstream induction of immune suppression by primary human melanoma tumor-associated fibroblasts (TAF).

Experimental Design: Primary human melanocytes and melanoma cell lines were transduced to express WT or V600E forms of BRAF, followed by gene expression analysis. The BRAF(V600E) inhibitor vemurafenib was used to confirm targets in BRAF(V600E)-positive melanoma cell lines and in tumors from melanoma patients undergoing inhibitor treatment. TAF lines generated from melanoma patient biopsies were tested for their ability to inhibit the function of tumor antigen-specific T cells, before and following treatment with BRAF(V600E)-upregulated immune modulators. Transcriptional analysis of treated TAFs was conducted to identify potential mediators of T-cell suppression.

Results: Expression of BRAF(V600E) induced transcription of interleukin 1 alpha (IL-1α) and IL-1β in melanocytes and melanoma cell lines. Further, vemurafenib reduced the expression of IL-1 protein in melanoma cell lines and most notably in human tumor biopsies from 11 of 12 melanoma patients undergoing inhibitor treatment. Treatment of melanoma-patient–derived TAFs with IL-1α/β significantly enhanced their ability to suppress the proliferation and function of melanoma-specific cytotoxic T cells, and this inhibition was partially attributable to upregulation by IL-1 of COX-2 and the PD-1 ligands PD-L1 and PD-L2 in TAFs.

Conclusions: This study reveals a novel mechanism of immune suppression sensitive to BRAF(V600E) inhibition, and indicates that clinical blockade of IL-1 may benefit patients with BRAF wild-type tumors and potentially synergize with immunotherapeutic interventions.

Introduction

Several human and animal studies have provided evidence that a major barrier to the success of immunotherapies are multiple mechanisms of pre-existing, localized, tumor-induced immune suppression (1, 2). Many of these mechanisms cause downregulation or inhibition of T-cell function and are common to multiple cancers, with their presence frequently associated with poor patient prognosis (3). T-cell suppression can be caused by tumor cells directly through the secretion of inhibitory cytokines such as IL-10, TGF-β, or VEGF, or through membrane expression of co-inhibitory molecules such as the PD-1 ligands PD-L1 and PD-L2 (4). Alternatively, tumors can secrete factors that serve to recruit and activate inhibitory immune cells such as regulatory T cells, myeloid-derived suppressor cells, or tumor-associated macrophages, which can in turn inhibit the function of tumor-infiltrating lymphocytes (TIL; ref. 5). A number of recent studies have implicated stromal fibroblasts within tumors as additional cell types capable of mediating immune suppression (6–8). The tumor stroma is composed largely of cells derived from the mesenchymal lineage, broadly described as tumor-associated fibroblasts (TAF; refs. 9, 10). These cells infiltrate and encapsulate the tumor parenchyma, are in proximity to infiltrating immune cells,
and respond to molecular cues from tumor cells, thus influencing metastatic potential and drug resistance (10–13). Research into the functional consequences of these interactions has shown that tumor and fibroblast-derived cytokines such as IL-1α or IL-1β are important in tumor progression as well as responses to therapy (11, 14–16). Further, several studies have implicated IL-1α and β as being enforcers of sterile inflammation in melanoma tumors, and as major mediators of myeloid cell chemotaxis; however, the ultimate effect of IL-1 signaling on adaptive immune responses in the tumor microenvironment remains unclear (17–21).

Although several mechanisms of immune suppression in cancer have now been identified, the means by which these mechanisms are initiated in tumors is still not well understood. One emerging hypothesis is that constitutive MAPK pathway activation in tumor cells leads to the downstream production of immunomodulatory factors. Supporting this idea, oncogenic RAS can upregulate IL-6 secretion, leading to the promotion of tumor growth (22, 23). Further, melanoma cell lines engineered to knock down BRAF(V600E) expression showed reduced production of IL-6, IL-10, and VEGF, cytokines that inhibit the T-cell stimulatory function of dendritic cells (24). In the present study, we analyzed how BRAF(V600E) signaling influences the expression of immunomodulatory genes within the melanoma tumor microenvironment. Our results reveal that mutated BRAF stimulates the production of IL-1α and β in tumor cells, which in turn can promote functional T-cell suppression through induction of the expression of PD-1 ligands and COX-2 by melanoma TAFs. Importantly, pharmacologic inhibition of BRAF(V600E) relieved this mode of immune suppression, indicating that patients may benefit from therapeutic approaches that combine the use of BRAF (V600E) inhibitors with T-cell-based immunotherapies.

**Materials and Methods**

**Cell culture and transduction**

WM793p2, A375, and T2 cells were cultured in RPMI-1640 medium (GIBCO) containing 10% FBS (GIBCO), 10 IU/mL penicillin (Cellgrow), and maintained at 37°C in 5% CO₂. The E1B-19L and KIL84-MEL cell lines, which were kindly provided by Etienne De Plaen (Ludwig Institute for Cancer Research, Brussels), were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM; GIBCO) containing 20% FBS (GIBCO), 10 IU/mL penicillin (Cellgrow), and 10 µg/mL streptomycin (Cellgrow). Dermal cell preparations were obtained from ScinCell and cultured in the melanocyte medium (ScinCell) provided. Primary neonatal epidermal melanocytes were obtained from ScinCell and cultured in Melanoxyte Medium with MS growth supplement (ScinCell). Patient biopsy-derived TIL and TAFs were available with institutional IRB approval and patient informed consent. TIL or tumor digests were maintained in RPMI-1640 medium (GIBCO) containing 10% FBS (GIBCO), 10 IU/mL penicillin (Cellgrow), 10 µg/mL streptomycin (Cellgrow), and supplemented with 200 IU/mL of IL-2 (Prometheus) unless otherwise indicated (48). TAFs were isolated from mixed tumor cell cultures on the basis of CD90 positivity and MCSP negativity by cell sorting. TAFs were isolated from melanoma biopsies from lymph nodes, soft tissue, lung, brain, and chest wall. BRAF WT and V600E plasmids were obtained from R. Marais (49). Genes were cloned into pDonor 222 (Invitrogen) by standard methodologies. These constructs were then sequenced and cloned into a self-inactivating bicistronic lentivirus expression vector (PLV401) containing the CMV promoter via LR reactions (Invitrogen; Supplementary Fig. S1). Lentivirus was generated by Lipofectamine 2000 transfection of the packaging cell line, 293T-METR, with packaging plasmids containing pR8.91, CMV-pVSVG, and the indicated expression vectors. Viral supernatants were collected at 48 hours and concentrated by ultra centrifugation. Dermal cell preparations and melanocytes were transduced at MOI of ~10, or by viral titration followed by selection of equivalently transduced lines based on GFP expression. Experiments using melanocytes transduced with BRAF or control expression vectors were carried out between 2 and 10 days after transduction.

**Patient samples**

Patients with metastatic melanoma possessing BRAF V600E mutations were enrolled on a clinical trial for treatment with a BRAF inhibitor (vemurafenib, RO5185426) and provided consent for tissue acquisition according to independent review board (IRB)-approved protocol. Tumor biopsies were carried out pretreatment (day 0) and at 10 to 14 days on treatment.

**Melanoma xenograft**

NOD/SCID mice were obtained from Jackson Laboratory. Mice were maintained in accordance with the institutional guidelines of MD Anderson Cancer Center.

---

**Translational Relevance**

This study implicates IL-1α and IL-1β as BRAF (V600E)-regulated genes that play a key immunosuppressive role within the melanoma tumor microenvironment. We identified a transcriptional program of response to IL-1 by melanoma TAFs, including upregulation of multiple known immunosuppressive genes such as PD-1 ligands (PD-L1 and PD-L2) and COX-2 (PTGS2), and showed that IL-1–responding TAFs suppress the immune function of tumor-reactive cytotoxic T lymphocytes (CTL). The clinical BRAF(V600E) inhibitor vemurafenib blocked IL-1α production in multiple melanoma cell lines tested, as well as in tumors derived from BRAF(V600E)-positive melanoma patients undergoing vemurafenib treatment. These results highlight the role of oncogenic BRAF in the induction of immune suppression in melanoma, and provide a strong rationale to combine the use of BRAF inhibitors with active immunotherapy approaches for the treatment of metastatic melanoma patients.

---

**Materials and Methods**

**Cell culture and transduction**

WM793p2, A375, and T2 cells were cultured in RPMI-1640 medium (GIBCO) containing 10% FBS (GIBCO), 10 IU/mL penicillin (Cellgrow), 10 µg/mL streptomycin (Cellgrow), and maintained at 37°C in 5% CO₂. The E1B-19L and KIL84-MEL cell lines, which were kindly provided by Etienne De Plaen (Ludwig Institute for Cancer Research, Brussels), were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM; GIBCO) containing 20% FBS (GIBCO), 10 IU/mL penicillin (Cellgrow), and 10 µg/mL streptomycin (Cellgrow). Dermal cell preparations were obtained from ScinCell and cultured in the melanocyte medium (ScinCell) provided. Primary neonatal epidermal melanocytes were obtained from ScinCell and cultured in Melanoxyte Medium with MS growth supplement (ScinCell). Patient biopsy-derived TIL and TAFs were available with institutional IRB approval and patient informed consent. TIL or tumor digests were maintained in RPMI-1640 medium (GIBCO) containing 10% FBS (GIBCO), 10 IU/mL penicillin (Cellgrow), 10 µg/mL streptomycin (Cellgrow), and supplemented with 200 IU/mL of IL-2 (Prometheus) unless otherwise indicated (48). TAFs were isolated from mixed tumor cell cultures on the basis of CD90 positivity and MCSP negativity by cell sorting. TAFs were isolated from melanoma biopsies from lymph nodes, soft tissue, lung, brain, and chest wall. BRAF WT and V600E plasmids were obtained from R. Marais (49). Genes were cloned into pDonor 222 (Invitrogen) by standard methodologies. These constructs were then sequenced and cloned into a self-inactivating bicistronic lentivirus expression vector (PLV401) containing the CMV promoter via LR reactions (Invitrogen; Supplementary Fig. S1). Lentivirus was generated by Lipofectamine 2000 transfection of the packaging cell line, 293T-METR, with packaging plasmids containing pR8.91, CMV-pVSVG, and the indicated expression vectors. Viral supernatants were collected at 48 hours and concentrated by ultracentrifugation. Dermal cell preparations and melanocytes were transduced at MOI of ~10, or by viral titration followed by selection of equivalently transduced lines based on GFP expression. Experiments using melanocytes transduced with BRAF or control expression vectors were carried out between 2 and 10 days after transduction.

**Patient samples**

Patients with metastatic melanoma possessing BRAF V600E mutations were enrolled on a clinical trial for treatment with a BRAF inhibitor (vemurafenib, RO5185426) and provided consent for tissue acquisition according to independent review board (IRB)-approved protocol. Tumor biopsies were carried out pretreatment (day 0) and at 10 to 14 days on treatment.

**Melanoma xenograft**

NOD/SCID mice were obtained from Jackson Laboratory. Mice were maintained in accordance with the institutional guidelines of MD Anderson Cancer Center.
Melanoma tumors were generated by subcutaneous injection of 10 million A375 cells on Day 0. Tumors were treated with PLX4720 (100 mg/kg body weight) on Day 7, administered by gavage on a daily basis for 3 days. Vehicle solution contained 3% dimethyl sulfoxide (DMSO) and 1% methylocellulose. Harvested tumors were divided in half for histology and transcriptional analysis. Experiments used 3 mice per group.

Reverse transcriptase polymerase chain reaction

Total RNA was isolated from cultured melanoma cell lines and A375 xenografts using the RNAqueous NA isolation kit from Ambion. One-step reverse transcriptase polymerase chain reaction (RT-PCR) was conducted using iScript (Bio-Rad) according to the manufacturer’s instructions. Primer sequences used are as follows: IL1aF: 5’-TGGCCCACTCAGGAAGGCTGC-3’, IL1bR: 5’-GTCATTGTCGACCTGCAGCAAG-3’, IL1bF: 5’-GGGCTCCTCCTCAGCAGCATG-3’, IL1bR: 5’-GTCATTGTCGACCTGCAGCAAG-3’. Gene-set enrichment analysis (GSEA) was carried out using the method described by Subramanian and colleagues. All of the tests in Figs. 2, 3, and 4 are 1-sided t-tests; asterisks indicate P-values of <0.05, if not explicitly provided. Tests in Fig. 5 are paired 1-sided t-tests.

Western blotting

Cell lysates were prepared from cultured TAFs. Protein content was normalized using the BCA method (Thermo-Fisher). Protein samples were separated on 10% SDS-PAGE and transferred to a PVDF membrane (Bio-Rad). Membranes were blocked in 5% nonfat milk, and incubated with primary anti-COX-2 at 1:1,000 dilution overnight at 4°C. Washed membranes were incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies for 2 hours at room temperature before chemiluminescent detection (GE Healthcare).

Immunohistochemistry

Immunohistochemical (IHC) staining for IL-1α, IL-1β, and alpha smooth muscle actin (αSMA) was carried out using the avidin–biotin complex kit (Vector Laboratories) on melanoma patient tumor samples before and following treatment with vemurafenib, or on untreated patient tumor biopsies. IHC staining was appropriately optimized in our lab, and control tissues were systemically used to avoid false-negative or false-positive staining. Percentages and staining intensities (0 to 3, minimum to maximum) of stained tumor cells were quantitated using microscopy and blinded pathological examination. IHC scores were calculated using the following equation: percentage positively stained cells × intensity score × 100.

Flow cytometric analyses

Analysis of surface antigens on melanoma cell lines and melanocytes was carried out by standard flow cytometric methods. Antibodies were obtained from the indicated suppliers, From: PD-L1 (M1H1), PD-L2 (MH18), AF647 labeled anti-rabbit IgG fab's (eBiosciences); CD8 (RPA-T8), Ki-67 (B56), CD25 (M-A251), IL-1α (AS10), CD90 (5E10; Becton Dickinson Biosciences); PD-1 (E112.2H7; Biolegend); MCSP (EP-1; Miltenyi Biotec), and BFAF (EP152Y; Epitomics). Intracellular antigens were stained after fixation and permeabilization using Foxp3 intracellular staining Kit (eBiosciences). Stained cells were analyzed using a FACScanto II flow cytometer, or a FacsCaliber flow cytometer (Becton Dickinson Biosciences). Data was analyzed using Flowjo analysis software (Treestar).

Cytokine detection

Supernatants from cell lines or co-cultures were collected and aliquots stored at −20°C before detection of interferon gamma (IFN-γ), IL-1α, and IL-1β, by standard ELISA methods according to manufacturer’s instructions (R&D Systems). For some experiments, supernatants were analyzed for multiple cytokines (IL-1α, IL-1β, IL-8, IL-6, IFN-γ, and TNF-α) by multiplex Luminex assays according to manufacturer’s instructions (Millipore).
TIL suppression assay

Foreskin-derived dermal cell preparations or melanoma TAFs were plated into 96-well flat-bottom plates and cultured until 80% confluent. IL-1α/β (1 ng/mL) or conditioned medium was added to the plates overnight. To test direct presentation, wells were washed before Mart-1 27L (AAGIGILTV) peptide pulsing (100 nmol/L, 3 hours, 37°C, serum-free medium). For third-party cell stimulation, T2 cells or irradiated CD40L-activated B cells were pulsed with peptide and added with 1:1 TIL at a 1:1 ratio to cultures. Proliferation was inferred by expression of cell-cycle protein Ki-67 in the MART-1 tetramer-binding CD8 T cells.
Supernatants were collected at the indicated times during the co-culture for IFN-γ analysis as described above. Melanoma cell line-conditioned medium was obtained from confluent cell cultures in T150 flasks containing 13 mL of medium after 24 hours with and without treatment with 1 μmol/L vemurafinib (Plexxikon). This treatment condition did not significantly alter the cell number per flask. Medium was centrifuged and 0.22 μmol/L filtered before use in assays. Blockade of PD-L1 and PD-L2 was achieved with the use of purified Azide-free PD-L1

Figure 2. Inhibition of BRAF(V600E) abrogates IL-1 expression in melanoma cell lines and patient tumors. A, RT-PCR analysis of IL-1α, IL-1β, and GAPDH transcripts in BRAF(V600E)-positive WM793p2 cells at different time points following treatment with 1 μmol/L vemurafenib. B, flow cytometric analysis showing intracellular IL-1β protein expression in live cell-gated WM793p2 cells 48 hours following treatment with titrated doses of PLX4032. C, RT-PCR analysis showing transcript levels of IL-1α, IL-1β, and CNX in 5 vemurafenib-treated melanoma cell lines expressing either wt BRAF (HS294T) or V600E-mutated BRAF (A375, EB16-MEL, KUL84-MEL, and WM793p2). Transcript levels were normalized to GAPDH expression and adjusted to corresponding baseline samples. D, immunohistochemical (IHC) analysis of IL-1α protein expression in tumor biopsies resected from 2 representative metastatic melanoma patients harboring the BRAF(V600E) mutation, both before and on vemurafenib treatment. E, summary of changes to IL-1α expression in response to vemurafenib treatment, as assessed by IHC analysis of 12 total melanoma patient tumor biopsy pairs analyzed.
Expression of BRAF (V600E) upregulates IL-1α/β in melanocytes and melanoma cells

In order to assess the downstream gene transcription profile induced by BRAF(V600E), we developed a lentiviral vector-based system to enforce its expression in primary human melanocytes, thus mimicking one of the presumed earliest events in melanomagenesis. A CMV promoter was used to drive expression of either wild-type (WT) BRAF or mutated BRAF(V600E), and eGFP expression driven by a downstream IRES element allowed for the flow cytometric sorting of transduced cells (Fig. 1A). As expected, GFP fluorescence correlated with expression of BRAF protein, and eGFP+ cells were sorted at 36 hours post-transduction and analyzed by Affymetrix microarray for changes in gene expression (Fig. 1B).

Ectopic expression of BRAF(V600E) in melanocytes specifically upregulated the transcription of a number of immunomodulatory genes (Fig. 1C). In addition to upregulating the expression of genes previously linked to oncogenic BRAF, including IL-6, IL-8, and VEGF, BRAF (V600E) also significantly increased the transcription of IL-1α and IL-1β genes (24, 25). Moreover, increased production of these cytokines was confirmed at the protein level by analyzing culture supernatants of transduced melanocytes (Fig. 1D). To determine whether these results were relevant for melanoma tumor cells, we transduced the HS294T melanoma cell line, which naturally expresses only WT BRAF. As shown in Fig. 1C, expression of BRAF(V600E) induced similarly elevated levels of IL-1α and -β transcripts compared with HS294T cells transduced with WT BRAF, or empty vector. Although the induced gene expression patterns between primary melanocytes and HS294T cells showed only partial overlap, the common upregulation of IL-1 in both cell types led us to hypothesize that BRAF(V600E) may be linked to IL-1-mediated inflammation in melanoma.

IL-1α and IL-1β expression has been widely documented in melanoma; however, some discrepancies exist in reports of its prevalence, in which IL-1α or -β positivity has ranged from 10% to 70% of samples analyzed (26–28). Our own

(M1H1) and PD-L2 (MIH18) antibodies (Becton Dickinson Biosciences) at 1.5 μg/mL doses. The COX-2 inhibitor NS398 (Cayman Chemicals) and DMSO vehicle controls were used at the time of IL-1 treatment at 50 μmol/L. IL-1α- and IL-1β-neutralizing antibodies (R&D Systems) were used at concentrations of 20 μg/mL each; isotype antibody (R&D Systems) controls were included where indicated.

Results

Expression of BRAF (V600E) upregulates IL-1α/β in melanocytes and melanoma cells

In order to assess the downstream gene transcription profile induced by BRAF(V600E), we developed a lentiviral vector-based system to enforce its expression in primary human melanocytes, thus mimicking one of the presumed earliest events in melanomagenesis. A CMV promoter was used to drive expression of either wild-type (WT) BRAF or mutated BRAF(V600E), and eGFP expression driven by a downstream IRES element allowed for the flow cytometric sorting of transduced cells (Fig. 1A). As expected, GFP fluorescence correlated with expression of BRAF protein, and eGFP+ cells were sorted at 36 hours post-transduction and analyzed by Affymetrix microarray for changes in gene expression (Fig. 1B).
was not strictly associated with tumors harboring nevi (Supplementary Fig. S1A). However, IL-1 expression frequency in advanced melanoma (and within a panel of human melanoma cell lines (Supplementary Fig. S2), only in BRAF(V600E)-expressing cell lines was IL-1α and -β production reduced in response to vemurafenib treatment. Collectively, these results showed that BRAF (V600E) inhibition by vemurafenib could effectively reduce IL-1 production in V600E-positive melanoma cell lines at doses considerably lower (<100×) than those typically found in the serum of vemurafenib-treated patients (8). In addition, control of IL-1α expression by BRAF was confirmed using direct shRNA-mediated knockdown of BRAF in a BRAF(V600E)-positive melanoma line (Supplementary Fig. S2).

For in vivo confirmation, NOD-SCID mice xenografted with human A375 tumors were treated with low doses of PLX4720 for 3 consecutive days, and growing tumors were excised for analysis (Supplementary Fig. S3A). As shown by quantitative RT-PCR (qRT-PCR), BRAF(V600E) inhibition reduced human IL-1α and IL-1β transcripts to nearly undetectable levels, confirming the in vitro findings. Further, consistent with the in vitro BRAF expression studies, transcription of IL-8 but not that of other control genes, was also abrogated (Supplementary Fig. S3B).

In addition, tumor biopsies were obtained from 12 Stage IV BRAF(V600E)-positive melanoma patients, both before and during vemurafenib treatment. IHC staining for IL-1α and IL-1β showed that 11 of 12 tumors stained positively for IL-1α before treatment, and that all 11 patients showed reductions in IL-1α protein levels on-treatment (Figs. 2D and 2E). As expected, IL-1β was much less prevalent, only being sparsely expressed by 2 of the tumors before treatment; however, both tumors showed reduced levels during vemurafenib treatment (not shown). These data collectively show that BRAF(V600E)-specific inhibition can block the transcription and production of IL-1α.

Figure 4. IL-1α upregulates the expression of immunosuppressive genes in melanoma-derived TAFs. A, phase-contrast images of 3 short-term cultured TAFs derived from melanoma patient biopsies (10–12). B, normalized relative transcriptional expression levels of PTGS2 (COX-2), PD-L1, and PD-L2 in 24-hour IL-1α-treated or untreated TAFs, as analyzed by Affymetrix gene expression array. C, Western blot analysis showing COX-2 and β-actin protein expression in 4 additional patient-derived TAF lines, before and 24 hours after treatment with IL-1α. D, surface expression of PD-1 ligands PD-L1 and PD-L2 on TAFs 24 hours after treatment with IL-1α or IFN-γ, as determined by flow cytometry. Data from 9 different melanoma-derived TAF lines are shown. Asterisks indicate statistical significance (P < 0.05); ns, not significant.

tissue microarray analysis of 147 human tumor samples showed that IL-1α is expressed at all stages of melanoma and in benign nevi at a frequency ranging from 63% to 88%, whereas IL-1β is expressed at a significantly lower overall frequency in advanced melanoma (~13%), and not at all in nevi (Supplementary Fig. S1A). However, IL-1 expression was not strictly associated with tumors harboring BRAF (V600E) mutations, as seen both in patient tumor samples and within a panel of human melanoma cell lines (Supplementary Fig. S1B–L). The observed expression of IL-1 in melanoma tumors lacking the BRAF(V600E) mutation indicates that other mechanisms, potentially including alternate pathways of MAPK pathway activation, may also induce its expression.

Pharmacologic inhibition of BRAF(V600E) abrogates IL-1 production in melanoma

In order to test the hypothesis that BRAF(V600E) was responsible for driving IL-1 production in melanoma, we measured the production of IL-1 by BRAF(V600E)-positive melanoma cell lines before and following exposure to the BRAF(V600E)-specific inhibitor vemurafenib (also known as PLX4032). As shown in Fig. 2A, 1 μmol/L vemurafenib treatment of the WM793p2 cell line resulted in a progressive reduction in both IL-1α and IL-1β mRNA transcripts, which reached maximal downregulation within 3 to 4 hours. Consistent with this result, vemurafenib treatment reduced IL-1β protein to nearly undetectable levels at doses as low as 0.1 μmol/L, as shown by intracellular staining and flow cytometric analysis (Fig. 2B). In addition, we tested 4 other IL-1–producing melanoma cell lines, 3 of which were positive for V600E (A375, EB16-MEL, and KUL84-MEL), and 1 that expressed WT BRAF (HS294T). As shown in Fig. 2C, only in BRAF(V600E)-expressing cell lines was IL-1α and -β production reduced in response to vemurafenib treatment. Collectively, these results showed that BRAF (V600E) inhibition by vemurafenib could effectively reduce IL-1 production in V600E-positive melanoma cell lines at doses considerably lower (<100×) than those typically found in the serum of vemurafenib-treated patients (8). In addition, control of IL-1α expression by BRAF was confirmed using direct shRNA-mediated knockdown of BRAF in a BRAF(V600E)-positive melanoma line (Supplementary Fig. S2).
in melanoma, thus altering the cytokine milieu within the tumor microenvironment.

IL–1-treated tumor-associated fibroblasts induce suppression of melanoma-specific CD8+ T-cells

We next explored the hypothesis that IL-1 production within the melanoma tumor microenvironment could be inducing functional T-cell suppression indirectly through resident stromal fibroblasts. In melanoma tumor samples, TIL are frequently found in close proximity to TAFs recognized by morphology or SMA expression; these TAFs surround tumor vessels, and often form physical barriers between TIL and tumor cells (Fig. 3A). Considering the importance of TIL for mediating tumor regressions in melanoma patients (29, 30), and their proximity to TAFs within the tumor microenvironment, we next tested whether TAFs were capable of suppressing CD8+ T-cell function and whether IL-1 could impact this suppression.
TAFs were isolated from cultured digests of human melanoma patient metastases by CD90 bead-positive selection. Melanoma TAFs from 6 different patients were then tested for suppressive function in co-culture with MART-1-specific TIL exposed to MART-1 peptide-pulsed T2 stimulator cells. Whereas untreated TAFs showed minor suppression of TIL cytokine production, IL-1α pretreatment reduced IFN-γ production by an average of 4- to 5-fold. Further, antibody-mediated neutralization of IL-1α/β abrogated the suppressive effect of IL-1 in combination with TAFs (Fig. 3B). In addition, T-cell function was assessed by measuring antigen-specific degranulation on the basis of CD107a surface staining. Consistent with the suppressive effects on cytokine production, 2 different MART-1-reactive TIL lines were significantly inhibited in their response to MART-1 peptide presentation in the presence of IL-1α-pretreated fibroblasts, as compared with untreated fibroblasts (Fig. 3C). Collectively, these results indicate that IL-1α is capable of driving functional, antigen-specific CTL suppression indirectly through the activation of melanoma-derived TAFs.

**IL-1 upregulates expression of immunosuppressive genes in melanoma-derived TAFs**

Because understanding the basic mechanisms of IL-1α-induced suppression by TAFs could inform more general clinical strategies to improve immunotherapies, we next carried out a global transcriptional analysis of TAFs treated with IL-1α, with our goal being to identify candidate immunomodulators that could mediate T-cell suppression in this context. Human TAFs were isolated and purified from 3 different melanoma patient tumors derived from metastases of lymph node, lung, and soft tissue (Fig. 4A). The TAFs were then treated with recombinant human IL-1α in culture for 24 hours and mRNA was isolated for Affymetrix-based gene expression analysis. We identified 197 genes that were differentially expressed by TAFs in response to IL-1α treatment, most of which were upregulated in all 3 TAFs (Supplementary Fig. S4A). GSEA analysis revealed a strong enrichment for genes associated with NF-kB activation and interferon responses (Supplementary Fig. S4B). These included a number of genes with immune-related functions, including multiple chemokines as well as several cytokines. Importantly, a number of the IL-1α-induced genes were known mediators of T-cell suppression (Supplementary Fig. S4C; Supplementary references 11 to 20). For functional studies, we decided to focus on 3 of these genes: PTGS2 (also known as COX-2), and the PD-1 ligands PD-L1 and PD-L2 (Fig. 4B). All 3 of these genes were among the most highly upregulated, are known to exert powerful suppressive effects on T cells, and their mechanisms of action have been relatively well-characterized in multiple cancer types (31, 32).

Augmented expression of the 3 gene products in response to IL-1α treatment was also confirmed in multiple, independently-derived melanoma TAFs. Western blot analysis showed increased levels of COX-2 protein (Fig. 4C), and flow cytometric analysis showed increased TAF surface expression levels of both PD-L1 and PD-L2 following IL-1α or IL-1β treatment (Figs. 4D and S5). IL-1α and IL-1β were both shown to be very potent inducers of PD-1 ligand expression, showing activity at concentrations as low as 1 pg/mL (Supplementary Fig. S6). Further, although IL-1α/β was not as effective as IFN-γ at inducing expression of PD-L1, it was equally effective at inducing expression of the higher affinity PD-1 ligand PD-L2 in all 9 TAFs analyzed (Figs. 4D and Supplementary Fig. S5). Collectively, these results show that TAFs exposed to low concentrations of IL-1α/β respond by rapidly stimulating the expression of at least 3 molecules known to directly induce CTL suppression.

**BRAF (V600E) induces T-cell suppression through IL-1-mediated upregulation of PD-1 ligands and COX-2 on TAFs**

We next assessed whether PD-1 ligand upregulation by TAFs can be directly attributed to IL-1 production induced by BRAF(V600E). In order to establish this link, we collected culture supernatants from melanocytes that were stably transduced to express either WT or mutated BRAF, and then exposed these supernatants to melanoma-derived TAFs overnight. Flow cytometric analysis revealed that conditioned media from BRAF(V600E)-transduced melanocytes, but not those transduced with WT BRAF or GFP vectors, was capable of upregulating surface expression of PD-L1 (Fig. 5A). Importantly, IL-1α/β antibody blockade abrogated this PD-L1 expression, showing that IL-1 was the mediator responsible for PD-1 ligand upregulation (Fig. 5A).

In order to determine whether pharmacologic BRAF (V600E) inhibition could relieve TAF-mediated T-cell suppression, we exposed 6 different melanoma-derived TAFs to supernatants from BRAF(V600E)-positive melanoma cell lines that were either untreated or treated with vemurafenib. Following overnight exposure to these supernatants, TAFs were co-cultured with MART-1-specific, PD-1-positive TIL, and MART-1 peptide-pulsed T2 target cells for 18 hours. The following day, culture supernatants were assessed for IFN-γ production. As shown in Fig. 5B, vemurafenib treatment resulted in a significant augmentation of T-cell IFN-γ production in all 6 TAFs analyzed. To ascertain whether IL-1α/β, COX-2, or PD-1 ligands played a role in mediating this suppression, we next carried out a similar experiment in the presence or absence of IL-1α/β or PD-L1/PD-L2 antibody blockade, or the COX-2 inhibitor NS398. Antibody neutralization of IL-1α/β in melanoma cell line supernatants partially relieved the MART-1 TIL functional suppression observed in co-cultures with TAFs (Fig. 5C). In addition, antibody neutralization of PD-1 ligands and COX-2 partly relieved TAF-mediated suppression, whereas combining the neutralization of IL-1α/β and PD-1 ligands with COX-2 inhibition augmented T-cell cytokine production even further. Although there was some variability in the extent of T-cell suppression mediated by the different TAF lines, overall the data were consistent with IL-1 mediating T-cell suppression at least partially through TAF upregulation of PD-1 ligands and COX-2. As expected, pretreatment of the melanoma cell lines with vemurafenib rendered IL-1α/β...
blockade, PD-1 ligand blockade, and COX-2 inhibition ineffective at facilitating increased cytokine secretion by T cells (Fig. 5C). Taken together, these experiments support a model of IL-1-induced T-cell suppression that is mediated through stromal TAFs and is sensitive to pharmacologic BRAF(V600E)-specific inhibition (Fig. 6).

Discussion

Starting with the observation that enforced expression of BRAF(V600E) in human melanocytes could induce the transcription of IL-1α and -β genes, we subsequently found that the V600E-specific inhibitor vemurafenib could conversely block IL-1 protein production in human melanoma cell lines and in melanoma tumor biopsies derived from patients undergoing inhibitor treatment. We further observed that IL-1 was an important regulator of immune suppression as mediated by tumor-associated stromal fibroblast cells, which could exert potent inhibitory effects on melanoma antigen-specific CTLs following exposure to IL-1α or -β. Treatment of human melanoma-derived TAFs with recombinant IL-1α/β led to upregulated transcription of several genes known to manifest immune suppression, and we showed that COX-2, PD-L1, and PD-L2 contributed to the induction of functional T-cell inhibition. This study delineates an important and novel link between oncogene activation in tumors and the resulting downstream effects on inflammation and immune suppression within the tumor microenvironment.

Over the past decade, a number of small-molecule inhibitors that target elements of the MAPK pathway and its downstream targets MEK and ERK have been tested in experimental clinical trials for cancer patients (33, 34). Such pathway inhibitors have adverse off-target effects on immune cells that can result in lymphopenia and increased frequency of infections (35–37). Because T cells require the MAPK pathway for antigen recognition and antitumor function, they are particularly sensitive to these off-target effects (38, 39). Further, strong evidence has been accumulating that the immune system can make a critical contribution to antitumor responses even in the context of non-immunotherapeutic treatments (40–43), with the emerging paradigm being that an intact immune system contributes significantly to the outcome of treatment, and may be critical for clearance of drug-resistant tumor cells and for prevention of recurrences (44). These findings have led many to propose combining BRAF(V600E) inhibition with immunotherapies to increase response rates, and our data strongly supports this concept (24, 45, 46). Recent clinical evidence indicates that vemurafenib and GSK2118436 therapy enhances CD8+ T cell infiltration of the tumor mass, which correlates with the degree of tumor shrinkage (47). This result is consistent with our findings, but it remains to be determined whether this clinical effect is due directly to V600E inhibitor-induced reduction of immune suppression within the tumor microenvironment, or to other factors.

Our study identifies BRAF(V600E)-induced IL-1 as being a key mediator of immune suppression in melanoma. Unlike other cytokines that impact T cells directly, IL-1 reinforces immune suppression indirectly through the stimulation of melanoma TAFs. A number of recent studies have highlighted the importance of stromal TAFs in promoting tumor cell survival and evasion of NK–cell-mediated antitumor immunity (7). Our results are experimentally consistent with these findings and show that IL-1α and -β can induce melanoma TAFs to directly inhibit the antitumor function of melanoma antigen-specific CD8+ T cells. Gene expression analysis showed that this IL-1–mediated suppression is likely mediated by a host of factors known to affect T-cell function as well as that of other lymphocytes (listed in Supplementary Fig. S4B), including but not limited to TAF expression of PD-1 ligands PD-L1 and PD-L2, and COX-2. Importantly, the location of TAFs within the architecture of the melanoma tumor microenvironment, frequently lining tumor vasculature and/or forming a physical barrier between TIL and tumor cells, indicates that TAFs are ideally located to mediate immune cell suppression in vivo.

Perhaps the most crucial aspect of this study is the finding that pharmacologic inhibition of BRAF(V600E) in melanoma cells can relieve TAF-mediated suppression of immune cell function and largely restore antitumor T-cell responses. These results are consistent with other recent studies, and, collectively, these results have important clinical implications that strongly support the notion of combining BRAF (V600E)-specific inhibitors with immune-based therapies. The emerging link between MAPK pathway activation and immune suppression, combined with the lack of off-target effects shown by mutated kinase-targeted agents, indicates that such combination approaches may show therapeutic synergy and result in significantly better and more durable...
clinical responses in V600E-positive melanoma patients. Further, our findings support the notion that patients harboring non–BRAF-mutated tumors may benefit from treatments that aim to combine immunotherapeutic approaches with IL-1 blockade.

Disclosure of Potential Conflicts of Interest
Michael A. Davies has served on advisory boards and received research funding from Roche-Genentech and GlaxoSmithKline. No potential conflicts of interest were declared by the other authors.

Authors' Contributions
Conception and design: J. S. Khalili, S. Liu, P. Hwu, G. Lizee
Development of methodology: S. Khalili, S. Liu, T. G. Rodriguez-Cruz, M-Y. Zhang, Y. Li, L. G. Radvanyi, P. Hwu, G. Lizee

Acknowledgments
The authors thank Luis Vence and Jonathan Kurie for critical reading of this manuscript, and Lyn McDevitt Duncan of Massachusetts General Hospital for providing a melanoma-progression TMA.

Grant Support
Financial support for this work was provided in part from the CPRIT grant RP110248, SPORE grant CA093459, CCSG grant NC08P30CA16672, and a charitable grant from Transocon.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 16, 2012; revised July 6, 2012; accepted July 13, 2012; published OnlineFirst July 31, 2012.

References

Writing, review, and/or revision of the manuscript: J. S. Khalili, M-Y. Zhang, D. T. Frederic, R. W. Joseph, C. Bernatchez, E. A. Grimm, L. G. Radvanyi, R. E. Davis, M. A. Davies, J. A. Wargo, P. Hwu, G. Lizee

Suppression study: E. A. Grimm, P. Hwu, G. Lizee

www.aacrjournals.org

Clin Cancer Res; 18(19) October 1, 2012 5339

Published OnlineFirst July 31, 2012; DOI: 10.1158/1078-0432.CCR-12-1632

Downloaded from clinncancers.aacrjournals.org on April 14, 2017. © 2012 American Association for Cancer Research.
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Jahan S. Khalili, Shujuan Liu, Tania G. Rodríguez-Cruz, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-1632

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/07/31/1078-0432.CCR-12-1632.DC1

Cited articles
This article cites 50 articles, 27 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/18/19/5329.full.html#ref-list-1

Citing articles
This article has been cited by 31 HighWire-hosted articles. Access the articles at:
/content/18/19/5329.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.